We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Calquence also maintained efficacy and a sustained safety profile at four years for previously treated patients in the company’s ASCEND trial. Read More